Should Investors Be Excited About Sarepta's Delay?

After the FDA announced that it would need more time to complete its review of Sarepta Therapeutics ' controversial therapy for a rare form of muscular dystrophy, investors clamored to buy the company's shares, sending themsoaring by 26.6% today.

Varney & Co.

Tune in for the Opening Bell Countdown

Weekdays at 9 AM ET on FBN

Personal Finance

Business Leaders

Will Speaker Ryan ever back Trump?

Washington Examiner Reporter Sarah Westwood and Republican Political Strategist Boris Epshteyn on Paul Ryan not supporting Trump and New Mexico's Gov. Susana Martinez not appearing at Donald Trump's rally.

ETFs

DNC Chair Debbie Wasserman Schultz on thin ice?

GOP Strategist Ford O'Connell, Fox News Political Contributor Tammy Bruce, Independent Women's Forum Senior Fellow Jillian Melchior and Democratic Strategist Karine Jean-Pierre on Donald Trump, Paul Ryan and DNC Chair Debbie Wasserman Schultz.

Technology